It has been shown that omeprazole treatment produces higher intragastric pH values in Helicobacter pylori positive subjects than in H pylori negative subjects. This study aimed to investigate the effect of curing H pyloni on the intragastric pH in both the presence and absence of omeprazole therapy. Twenty four hour intragastric pH recordings were performed before and after a one week course of omeprazole (20 mg once daily) in 18 H pyloni positive subjects and were repeated after the infection had been cured. In We tested the hypotheses that intragastric pH in the absence of omeprazole administration is unchanged by the cure of H pylori and that omeprazole treatment produces lower intragastric pH values after H pylori infection has been cured.
Our observation that omeprazole produced higher intragastric pH values in Helicobacter pylori infected than in uninfected subjects' suggests that there may be a direct interaction between H pylori infection and omeprazole. Our findings were based, however, on a comparison of two separate groups of subjects and it is therefore arguable that the difference in response to omeprazole might have been related, for example, to a difference in susceptibility to Hpylori infection. If this had been the case, cure of H pylori infection would not have produced a change in the observed effect of omeprazole. We therefore investigated the effect of omeprazole on intragastric pH in subjects before and after cure of H pylori infection.
We tested the hypotheses that intragastric pH in the absence of omeprazole administration is unchanged by the cure of H pylori and that omeprazole treatment produces lower intragastric pH values after H pylori infection has been cured.
Methods

STUDY POPULATION
Eighteen H pylori positive subjects (11 men, seven women, aged 22-40 years) participated in the study. All were healthy, with no history of gastrointestinal disease or other illness and no current gastrointestinal symptoms. At the time of enrolment, subjects took no medication except oral contraceptives or paracetamol. Subjects were not included in the study if they had a history of alcohol or drug abuse. Smokers were not excluded but they were asked to refrain from smoking during the pH studies. Subjects in whom gastroesophageal reflux disease or peptic ulcer disease were diagnosed at entry were not included in the study. All subjects gave written, informed consent, and the study was conducted according to the declaration of Helsinki. Two fasting baseline breath samples were collected just before the subjects ate a standardised breakfast. Thereafter, the subjects took 100 mg of 13C urea dissolved in 200 ml of water and breath samples were collected at 20 and 60 minutes. The ratio of 13C/12C was measured by mass spectrometry. The difference between the baseline and test ratios was compared with a reference value and the results were expressed as excess delta 13C02 per mil (excess 8 %o), given a measure of increased urease activity.34 An excess 8 %o value of >5 was considered to be positive for H pylori infection.
Fasting blood samples from each subject were collected for determination of anti-H pylori antibodies. Sera were separated by centrifugation at 4°C for 10 minutes, and stored at -80°C for later analysis. H pylorn antibodies were measured by a specific ELISA (Roche). The test was defined as positive for H pylori infection if a value >10 U/ml was obtained.
ENDOSCOPIC BIOPSIES
Three biopsy specimens were obtained from the corpus and three from the antrum. Two biopsies from each location were placed in 10% buffered formalin for histological examination. All samples were examined by the same pathologist (MS) and processed in a standardised manner. Results Eighteen subjects completed the study. Mild diarrhoea was reported by two subjects who were taking omeprazole and amoxycillin and by one subject who was taking omeprazole, amoxycillin, and clarithromycin. One subject reported taste disturbance during omeprazole, amoxycillin, and clarithromycin administration. No adverse event prompted withdrawal of subjects from the study and all symptoms resolved after stopping treatment.
In one subject, one recording had to be repeated within 24 hours of the initial recording because of electrode failure.
Omeprazole and amoxycillin cured the H pyloni infection in five of eight subjects.
Omeprazole, amoxycillin, and clarithromycin cured the H pylori infection in the three remaining subjects with persistent infection and in the 10 subsequent subjects for whom this was the initial treatment regimen. Thus, no subject had to be withdrawn after the second antimicrobial treatment because of persistent H pylori infection.
INTRAGASTRIC pH-METRY
In the absence of omeprazole, the mean 24 hour pH plots show that nocturnal pH was higher during H pylori infection that after cure (Fig 2) . During omeprazole treatment, the gastric pH was higher throughout the entire recording before the cure of H pylori infection. (Fig 3) . There was, however, a fall in the late nocturnal pH from 1 -6 (1.3, 4.3) before cure to 1.2 (0.9, 1.5) after cure (p=0.005) ( Table I) . Omeprazole treatment produced a higher median 24 hour gastric pH before cure (5.4; 4.3, 6.0) than afterwards (3.6; 2.1, 4.4; p<0-001), and this difference was observed during all predefined time periods (Table I) . The H+ activity observed during omeprazole treatment before H pylori cure was lower than that observed afterwards. However, the omeprazole induced fall in H+ activity before cure was similar to that produced afterwards (Table II) .
BREATH TEST AND SEROLOGY RESULTS
Before cure of H pylon infection, negative breath test results were observed in three subjects one week after omeprazole treatment (Fig 4: upper panel, left) Omeprazole treatment erosion in the corpus. After cure, no epithelial breaks were observed. Giant folds were not observed in any subject during endoscopies. The total score of H pylori associated gastritis decreased in both the antrum and corpus four weeks after stopping the antimicrobial therapy (p<0001; Fig 5) . Neither atrophy nor intestinal metaplasia were found in any of the biopsy specimens. 
